Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$1.42 - $2.02 $23,359 - $33,229
-16,450 Reduced 61.99%
10,088 $19,000
Q4 2023

Feb 14, 2024

SELL
$1.11 - $1.51 $73,031 - $99,348
-65,794 Reduced 71.26%
26,538 $37,000
Q3 2023

Nov 14, 2023

SELL
$1.55 - $2.23 $508,799 - $732,015
-328,258 Reduced 78.05%
92,332 $145,000
Q2 2023

Aug 14, 2023

BUY
$1.72 - $2.57 $507,355 - $758,083
294,974 Added 234.82%
420,590 $908,000
Q1 2023

May 15, 2023

SELL
$1.88 - $2.5 $69,413 - $92,305
-36,922 Reduced 22.72%
125,616 $263,000
Q4 2022

Feb 14, 2023

SELL
$2.02 - $2.49 $35,301 - $43,515
-17,476 Reduced 9.71%
162,538 $355,000
Q3 2022

Nov 14, 2022

BUY
$2.79 - $4.15 $4,065 - $6,046
1,457 Added 0.82%
180,014 $540,000
Q2 2022

Aug 15, 2022

SELL
$2.63 - $5.61 $149,068 - $317,974
-56,680 Reduced 24.09%
178,557 $505,000
Q1 2022

May 16, 2022

SELL
$4.75 - $7.54 $1.2 Million - $1.9 Million
-251,756 Reduced 51.7%
235,237 $1.26 Million
Q4 2021

Feb 14, 2022

SELL
$7.29 - $9.5 $398,967 - $519,916
-54,728 Reduced 10.1%
486,993 $3.64 Million
Q3 2021

Nov 15, 2021

BUY
$4.22 - $12.48 $2.23 Million - $6.58 Million
527,275 Added 3649.97%
541,721 $4.92 Million
Q2 2021

Aug 16, 2021

BUY
$3.62 - $4.88 $52,294 - $70,496
14,446 New
14,446 $70,000
Q1 2021

May 17, 2021

SELL
$3.53 - $8.06 $165,295 - $377,417
-46,826 Closed
0 $0
Q4 2020

Feb 16, 2021

SELL
$3.07 - $4.66 $324,339 - $492,319
-105,648 Reduced 69.29%
46,826 $182,000
Q3 2020

Nov 16, 2020

BUY
$3.23 - $5.39 $65,733 - $109,691
20,351 Added 15.4%
152,474 $492,000
Q2 2020

Aug 14, 2020

BUY
$2.55 - $4.58 $173,027 - $310,771
67,854 Added 105.58%
132,123 $587,000
Q1 2020

May 15, 2020

BUY
$2.17 - $7.06 $139,463 - $453,739
64,269 New
64,269 $180,000

Others Institutions Holding LIFE

About aTYR PHARMA INC


  • Ticker LIFE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,625,000
  • Market Cap $53.2M
  • Description
  • aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for ...
More about LIFE
Track This Portfolio

Track Two Sigma Investments, LP Portfolio

Follow Two Sigma Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.